The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Canadian doctors and scientists say Robert F. Kennedy Jr.'s defunding of mRNA vaccine development projects will have negative ...

Many health officials predict HHS Secretary Robert F. Kennedy Jr's action could hurt the country’s ability to respond quickly to the next pandemic.

But it is possible to get the sniffles — or worse — in the summer. Federal data released Friday, for example, shows COVID-19 is trending up in many parts of the country, with emergency department ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

This week, President Donald Trump called Operation Warp Speed, a public-private federal program that helped speed up the ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...